<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944084</url>
  </required_header>
  <id_info>
    <org_study_id>HS-RBE-2016</org_study_id>
    <nct_id>NCT02944084</nct_id>
  </id_info>
  <brief_title>Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract</brief_title>
  <official_title>Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Economics and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The oral absorption and urinary excretion kinetics of the bioactive ingredients from rice
      bran (gamma-oryzanol, tocotrienols, tocopherols and ferulic acid esters) after incorporation
      into an oat porridge (oat porridge) compared to unprocessed rice bran extract oil were
      investigated. The influence of the type of preparation (with water vs. milk) of porridge on
      the bioavailability of the bioactive compounds was compared. The study followed a single dose
      (2 g rice bran extract), randomized, three armed crossover study design with ≥1-week washout
      periods. Plasma and urine samples were collected at intervals up to 24 h after intake.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total alfa, beta, gamma and delta tocopherols and tocotrienols [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total ferulic acid [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total ferulic acid after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total gamma-oryzanol [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total total alfa, beta, gamma and delta tocopherols and tocotrienols [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total ferulic acid [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total ferulic acid after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total gamma-oryzanol [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total gamma-oryzanol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total alfa, beta, gamma and delta tocopherols and tocotrienols [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total ferulic acid [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total ferulic acid after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total gamma-oryzanol [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total gamma-oryzanol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total Vitamin E metabolites [nmol/g creatinine]</measure>
    <time_frame>0-24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total ferulic acid [nmol/g creatinine]</measure>
    <time_frame>0-24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total gamma-oryzanol [nmol/g creatinine]</measure>
    <time_frame>0-24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma-glutamyl transferase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL/HDL cholesterol ratio</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate [mL/min]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose [mg/dL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Safety After Oral Intake</condition>
  <condition>Pharmacokinetics After Oral Intake</condition>
  <arm_group>
    <arm_group_label>Rice bran extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 g of unprocessed rice bran extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Porridge in water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Porridge in milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rice bran extract</intervention_name>
    <arm_group_label>Rice bran extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Porridge in water</intervention_name>
    <arm_group_label>Porridge in water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Porridge in milk</intervention_name>
    <arm_group_label>Porridge in milk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Volunteers with blood chemistry values within normal ranges

        Age 18 to 35 years

        BMI 19 to 25 kg per m2

        Exclusion Criteria:

        Pregnancy or lactation

        Alcohol and or drug abuse

        Use of dietary supplements or any medications except contraceptives

        Any known malignant, metabolic and endocrine diseases

        Previous cardiac infarction

        Dementia

        Participation in a clinical trial within the past 1 week prior to recruitment

        Smoking

        Physical activity of more than 5 h per wk

        Lactose intolerance

        Milk intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frank, Prof. Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nutrition-research.de/</url>
    <description>Website of the research group</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Rice bran extract</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Gamma-oryzanol</keyword>
  <keyword>Ferulic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rice bran oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

